Trial Profile
"NGR005: Pilot study of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin-based regimen in patients wit metastatic colorectal cancer"
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs NGR-TNF (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors AGC Biologics
- 22 Sep 2010 Status changed from active, no longer recruiting to completed, according to a MolMed media release.
- 22 Sep 2010 Results published in Annals of Oncology, according to a MolMed media release.
- 19 May 2010 Planned end date changed from Jun 2010 to Oct 2010 as reported by ClinicalTrials.gov.